Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II pilot study of cetuximab plus weekly paclitaxel in first-line recurrent or metastatic head and neck squamous cell carcinoma
2005-003010-15Phase 2Completed
- Sponsor
- Grupo Español de Tratamiento de Tumores de Cabeza y Cuello
- Start
- Nov 2005
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cetuximab and paclitaxel in head and neck squamous cell carcinoma (HNSCC), sponsored by Grupo Español de Tratamiento de Tumores de Cabeza y Cuello. Primary endpoint: Confirmed best overall tumor response. Started Nov 2005; status: completed.
02
Drugs
cetuximabpaclitaxel
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on 2005-003010-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-003010-15.